Spots Global Cancer Trial Database for vaccinia virus
Every month we try and update this database with for vaccinia virus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma | NCT01171651 | Carcinoma, Hepa... | JX-594 followed... | 18 Years - | SillaJen, Inc. | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | NCT00625456 | Melanoma Lung Cancer Renal Cell Carc... Squamous Cell C... | Recombinant Vac... | 18 Years - | SillaJen, Inc. | |
| A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | NCT01443260 | Peritoneal Carc... | GL-ONC1 | 18 Years - | Genelux Corporation | |
| Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | NCT01380600 | Carcinoma, Colo... | Recombinant Vac... | 18 Years - | SillaJen, Inc. | |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | NCT01394939 | Colorectal Carc... CRC | JX-594 Irinotecan | 18 Years - | SillaJen, Inc. | |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | NCT03954067 | Metastatic Canc... Solid Tumors Advanced Cancer | ASP9801 Pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | NCT00794131 | Advanced Cancer... | GL-ONC1 | 18 Years - | Genelux Corporation | |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | NCT04725331 | Metastatic Canc... Soft Tissue Sar... Merkel Cell Car... Melanoma Triple Negative... Non Small Cell ... | BT-001 Pembrolizumab [... | 18 Years - | Transgene | |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | NCT01394939 | Colorectal Carc... CRC | JX-594 Irinotecan | 18 Years - | SillaJen, Inc. | |
| Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin | NCT02017678 | Ovarian Cancer | JX-594 | 18 Years - | Mount Sinai Hospital, Canada | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | NCT01169584 | Neuroblastoma Rhabdomyosarcom... Lymphoma Wilm's Tumor Ewing's Sarcoma | Recombinant Vac... | 2 Years - 21 Years | SillaJen, Inc. | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | NCT01169584 | Neuroblastoma Rhabdomyosarcom... Lymphoma Wilm's Tumor Ewing's Sarcoma | Recombinant Vac... | 2 Years - 21 Years | SillaJen, Inc. | |
| A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma | NCT00629759 | Neoplasms, Live... | JX-594: Recombi... | 18 Years - | Jennerex Biotherapeutics | |
| GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | NCT02759588 | Ovarian Cancer Peritoneal Carc... Fallopian Tube ... | GL-ONC1 alone, ... | 21 Years - | Genelux Corporation | |
| Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact | NCT05376527 | Oncolytic Virot... | Double Recombin... | 18 Years - | "Oncostar" LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
